Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024

Athira Pharma, Inc. said the development of fosgonimeton for patients with mild-to moderate Alzheimer's disease remains on a solid footing following an interim analysis of an ongoing Phase II/III clinical trial. The trial passed an interim efficacy and futility analysis by a data monitoring committee that recommended the LIFT-AD study in patients with mild-to-moderate Alzheimer's disease continue, the company announced on 17 October.

"What has us especially excited is the fact that this unblinded analysis supports the potentially clinically meaningful activity of [fosgonimeton]...